[Ketoanalogs in association with high protein diet in chronic kidney failure]

English Mengarelli C, Augustovski F, Alfie V, Argento F, Klappenbach R, Pichon-Riviere A, Ciapponi A, Bardach A, Alcaraz A, García Martí S.
Record ID 32018001594
Spanish
Original Title: Cetoanálogos asociados a dieta hipoproteica en insuficiencia renal crónica
Authors' recomendations: No high-quality evidence has been found on the impact that the use of ketoanalogs associated with high-protein diets may have on mortality, delayed initiation of renal replacement therapy or quality of life in patients with chronic kidney failure Moderate-quality evidence suggests that their use (when compared with high-protein diets with no supplementation) would improve the glomerular filtration rate in patients with moderate and severe chronic kidney disease –with glomerular filtration rates higher than 18 mL/min/1.73 m2- and plasma phosphorus levels, with no adverse impact on the patient nutrition. Low-quality evidence suggests that it might have minor benefits in mortality in patients at early stages, prior to renal replacement therapy initiation. The KDOQUI clinical practice guidelines and a consensus of countries using ketoanalogs as food supplement (Germany, Hungary, Czech Republic, Italy, China, Mexico, Brazil) recommend its use in adult patients with kidney disease who have a glomerular filtration rate lower than 30 mL/min (Stages 3-5), who are stable, controlled by a follow-up team (Nephrologist and Nutritionist), who have indication and follow a low or very low protein diet (0.60 g to 0.3 g/kg/day). In high-income countries, ketoanalogs are classified as food supplement and they are not under the scope of regulatory agencies. No economic evaluations or budget impact analyses at local level have been found.
Details
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Kidney Failure, Chronic
  • Keto Acids
  • Diet, Ketogenic
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.